Clinical Trial Update: A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BMS-232632 with efavirenz, each combined with Zidovudine-Lamivudine, in HIV infection; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BMS-232632
• COMBIVIR (Lamivudine and Zidovudine)
• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED